73963-62-9

Basic information

• Product Name: 6-[4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL) BUTOXY]-2(1H)-QUINOLINONE
• Synonyms: OPC-13015;6-[4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL) BUTOXY]-2(1H)-QUINOLINONE;3,4-Dehydro Cilostazol;1H-tetrazol-5-yl)butoxy]-;2(1H)-Quinolinone, 6-[4-(1-cyclohexyl-;OPC-13015: 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)propoxy]-2(1H)-Quinolinone;Cilostazol Related Compound B (50 mg) (6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-1H-quinolin-2-one);OPC-13015: 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl) butoxy]-2(1H)-Quinolinone
• CAS NO: 73963-62-9
• Molecular Formula: C₂₀H₂₅N₅O₂
• Molecular Weight: 367.44
• Product Categories: Various Metabolites and Impurities;Metabolites & Impurities
• Mol File: 73963-62-9.mol
• Article Data: 4

Chemical Properties

• Melting Point: 179-180°C
• Boiling Point: 675.937°C at 760 mmHg
• Flash Point: 362.594°C
• Appearance: /
• Density: 1.342g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.676
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), DMSO (Slightly, Heated), Methanol (Slightly, Heated)
• BRN: 4273617
• CAS DataBase Reference: 6-[4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL) BUTOXY]-2(1H)-QUINOLINONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-[4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL) BUTOXY]-2(1H)-QUINOLINONE(73963-62-9)
• EPA Substance Registry System: 6-[4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL) BUTOXY]-2(1H)-QUINOLINONE(73963-62-9)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 73963-62-9(Hazardous Substances Data)

Usage

Chemical Properties

Off-White to Beige Solid

Uses

Different sources of media describe the Uses of 73963-62-9 differently. You can refer to the following data:
1. A metabolite of Cilostazol.
2. A metabolite of Cilostazol

InChI:InChI=1/C20H25N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h9-12,14,16H,1-8,13H2,(H,21,26)

Upstream product

• 19315-93-6 6-hydroxy-1H-quinolin-2-one 
• 73963-42-5 1-cyclohexyl-5-(4-chlorobutyl)-1,2,3,4-tetrazole 
• 54197-66-9 3,4-dihydro-6-hydroxy-2(1H)-quinolinone 

Downstream Products

• 135498-83-8 <(cyclohexyl-1 tetrazolyl-5)-4 butoxy>-6 chloro-2 quinoleine 
• 135498-81-6 <(cyclohexyl-1 tetrazolyl-5)-4 butoxy>-7 tetrazolo <1,5-a> quinoleine 
• 135498-80-5 <(cyclohexyl-1 tetrazolyl-5)-4 butoxy>-7 methyl-3 triazolo <4,3-a> quinoleine 
• 135498-79-2 <(cyclohexyl-1 tetrazolyl-5)-4 butoxy>-7 triazolo <4,3-a> quinoleine 
• 135498-82-7 <(cyclohexyl-1 tetrazolyl-5)-4 butoxy>-6 hydrazino-2 quinoleine 

Relevant articles and documents

Synthesis of related substances of cilostazol

The impurities in API of cilostazol were detected by LC/MS during the process development. The structures of two impurities 6 and 7 and the related formation mechanisms were proposed. Synthesis of 6 and 7 was conducted for confirmation of the speculated structures.

Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. II. 6-[3-(1-Cyclohexyl-5-tetrazolyl)propoxy]-1,2-dihydro-2-oxoquinoline and related compounds

A series of ω-(1-substituted-5-tetrazolylalkoxy)-2-oxoquinolines was synthesized and tested for inhibitory activity towards collagen- and adenosine diphosphate (ADP)-induced aggregation of rabbit blood platelets in vitro. These compounds were prepared by the reaction of 1-substituted-5-(ω-chloroalkyl)-tetrazoles and hydroxy-2-oxoquinolines in the presence of a base. Among them, 6-[3-(1-cyclohexyl-5-tetrazolyl)propoxy]-1,2-dihydro-2-oxoquinoline (IVb) was found to have the most potent inhibitory activity. The structure-activity relationships are discussed.